Display Settings:

Format

Send to:

Choose Destination
    Eur Neurol. 2004;51(2):89-97. Epub 2004 Jan 28.

    The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria.

    Source

    Department of Neurology, University of Essen, Hufelandstrasse 55, DE-45122 Essen, Germany. h.diener@uni-essen.de

    Abstract

    This is an independent reanalysis of a randomised, placebo-controlled parallel-group study on the efficacy and tolerability of a special butterbur root extract (Petadolex) for the prophylaxis of migraine. The original protocol and analysis had a number of major shortcomings. In order to follow regulatory requirements, an independent reanalysis of the original data was performed. Following a 4-week baseline phase, 33 patients were randomised to treatment with two capsules 25 mg butterbur twice a day and 27 to placebo. The mean attack frequency per month decreased from 3.4 at baseline to 1.8 after 3 months (p = 0.0024) in the verum group and from 2.9 to 2.6 in the placebo group (n.s.). The responder rate (improvement of migraine frequency > or =50%) was 45% in the verum group and 15% in the placebo group. Butterbur was well tolerated. This small trial indicates that butterbur may be effective in the prophylaxis of migraine.

    Copyright 2004 S. Karger AG, Basel

    PMID:
    14752215
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for S. Karger AG, Basel, Switzerland

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk